Cargando…

Plasma MIR-212-3p as a biomarker for acute right heart failure with pulmonary artery hypertension

BACKGROUND: Acute right heart failure occurs in patients with pulmonary artery hypertension (PAH) with exposure to acute inflammation, the mortality rate is very high when right heart failure occurs. Biomarkers that can be used to detect acute right heart failure in patients with pulmonary hypertens...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Yue, Li, Renhua, Cao, Yanan, Dai, Sisi, Luo, Sumei, Guo, Qulian, Wang, E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7791226/
https://www.ncbi.nlm.nih.gov/pubmed/33437770
http://dx.doi.org/10.21037/atm-20-1653a
_version_ 1783633565927342080
author Yang, Yue
Li, Renhua
Cao, Yanan
Dai, Sisi
Luo, Sumei
Guo, Qulian
Wang, E.
author_facet Yang, Yue
Li, Renhua
Cao, Yanan
Dai, Sisi
Luo, Sumei
Guo, Qulian
Wang, E.
author_sort Yang, Yue
collection PubMed
description BACKGROUND: Acute right heart failure occurs in patients with pulmonary artery hypertension (PAH) with exposure to acute inflammation, the mortality rate is very high when right heart failure occurs. Biomarkers that can be used to detect acute right heart failure in patients with pulmonary hypertension need to be studied. METHODS: A PAH rat model was established using monocrotaline, and lipopolysaccharide was used to induce acute right heart failure. The Agilent rat miRNA microarray, Gene Ontology (GO) analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis were used to assess the microRNA expression of PAH rats. The expression of up- and downregulated miRNAs in plasma from PAH patients with acute right heart failure was validated with quantitative reverse transcription polymerase chain reaction (qRT-PCR). Then, the Wilcoxon matched paired test and receiver operating characteristic (ROC) curve analysis were performed. RESULTS: Thirty-three miRNAs were upregulated, and 7 miRNAs were downregulated in plasma of PAH rats with acute right heart failure. In the plasma of PAH patients, the miR-212-3p level was inversely correlated with the level of NT-pro BNP, and the area under the ROC curve was 0.751. CONCLUSIONS: These results suggest that the reduction of the expression of MIR-212-3p may be a biomarker for PAH patients with right heart dysfunction.
format Online
Article
Text
id pubmed-7791226
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-77912262021-01-11 Plasma MIR-212-3p as a biomarker for acute right heart failure with pulmonary artery hypertension Yang, Yue Li, Renhua Cao, Yanan Dai, Sisi Luo, Sumei Guo, Qulian Wang, E. Ann Transl Med Original Article BACKGROUND: Acute right heart failure occurs in patients with pulmonary artery hypertension (PAH) with exposure to acute inflammation, the mortality rate is very high when right heart failure occurs. Biomarkers that can be used to detect acute right heart failure in patients with pulmonary hypertension need to be studied. METHODS: A PAH rat model was established using monocrotaline, and lipopolysaccharide was used to induce acute right heart failure. The Agilent rat miRNA microarray, Gene Ontology (GO) analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis were used to assess the microRNA expression of PAH rats. The expression of up- and downregulated miRNAs in plasma from PAH patients with acute right heart failure was validated with quantitative reverse transcription polymerase chain reaction (qRT-PCR). Then, the Wilcoxon matched paired test and receiver operating characteristic (ROC) curve analysis were performed. RESULTS: Thirty-three miRNAs were upregulated, and 7 miRNAs were downregulated in plasma of PAH rats with acute right heart failure. In the plasma of PAH patients, the miR-212-3p level was inversely correlated with the level of NT-pro BNP, and the area under the ROC curve was 0.751. CONCLUSIONS: These results suggest that the reduction of the expression of MIR-212-3p may be a biomarker for PAH patients with right heart dysfunction. AME Publishing Company 2020-12 /pmc/articles/PMC7791226/ /pubmed/33437770 http://dx.doi.org/10.21037/atm-20-1653a Text en 2020 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Yang, Yue
Li, Renhua
Cao, Yanan
Dai, Sisi
Luo, Sumei
Guo, Qulian
Wang, E.
Plasma MIR-212-3p as a biomarker for acute right heart failure with pulmonary artery hypertension
title Plasma MIR-212-3p as a biomarker for acute right heart failure with pulmonary artery hypertension
title_full Plasma MIR-212-3p as a biomarker for acute right heart failure with pulmonary artery hypertension
title_fullStr Plasma MIR-212-3p as a biomarker for acute right heart failure with pulmonary artery hypertension
title_full_unstemmed Plasma MIR-212-3p as a biomarker for acute right heart failure with pulmonary artery hypertension
title_short Plasma MIR-212-3p as a biomarker for acute right heart failure with pulmonary artery hypertension
title_sort plasma mir-212-3p as a biomarker for acute right heart failure with pulmonary artery hypertension
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7791226/
https://www.ncbi.nlm.nih.gov/pubmed/33437770
http://dx.doi.org/10.21037/atm-20-1653a
work_keys_str_mv AT yangyue plasmamir2123pasabiomarkerforacuterightheartfailurewithpulmonaryarteryhypertension
AT lirenhua plasmamir2123pasabiomarkerforacuterightheartfailurewithpulmonaryarteryhypertension
AT caoyanan plasmamir2123pasabiomarkerforacuterightheartfailurewithpulmonaryarteryhypertension
AT daisisi plasmamir2123pasabiomarkerforacuterightheartfailurewithpulmonaryarteryhypertension
AT luosumei plasmamir2123pasabiomarkerforacuterightheartfailurewithpulmonaryarteryhypertension
AT guoqulian plasmamir2123pasabiomarkerforacuterightheartfailurewithpulmonaryarteryhypertension
AT wange plasmamir2123pasabiomarkerforacuterightheartfailurewithpulmonaryarteryhypertension